<DOC>
	<DOCNO>NCT02144922</DOCNO>
	<brief_summary>Although statin reduce cardiac event hypertensive patient cardiovascular risk factor , effect statin coronary flow reserve ( CFR ) examine patient . The investigator hypothesize pitavastatin added standard antihypertensive therapy superior placebo improve CFR hypertensive patient cardiovascular risk , try examine hypothesis double-blind , randomize comparison study use Doppler echocardiography .</brief_summary>
	<brief_title>Effect Pitavastatin Coronary Flow Reserve Hypertensive Patients</brief_title>
	<detailed_description>Statin treatment improve coronary flow reserve ( CFR ) decrease cardiac morbidity mortality patient coronary artery disease ( CAD ) hypercholesterolemia . Endothelial dysfunction impairment coronary microcirculation also observe hypertensive patient cardiovascular risk factor . However , measurement CFR rarely perform hypertensive patient without CAD , CFR could invasively measure use Doppler guide wire cardiac catheterization laboratory . Recent advance echocardiographic image technique make possible measure coronary flow velocity CFR , highly correlate CFR measure invasive mean . Lipid lower statin provide beneficial effect patient average level serum total cholesterol Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm ( ASCOT-LLA ) study conduct hypertensive patient cardiovascular risk . Improvements endothelial dysfunction CFR may relate beneficial effect statin hypertensive patient without hypercholesterolemia , effect statin CFR examine patient . Accordingly , investigator try examine hypothesis pitavastatin add standard antihypertensive therapy hypertensive patient cardiovascular risk superior placebo improve CFR double-blind , randomize comparison study use Doppler echocardiography .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Controlled Hypertension : treat SBP &lt; 140 mmHg DBP &lt; 90 mmHg LDL cholesterol ≥ 130mg/dL Patients statinnaive state , define receive statin therapy 6 month previous 12 month . Any 1 cardiovascular risk factor require : smoking , age 55 ( men ) 65 ( woman ) , history cerebrovascular event , family history early CHD age 55 , HDL cholesterol &lt; 40 mg/dL A previous history intolerance hypersensitivity statins Uncontrolled hypertension ; SBP≥140 mmHg DBP≥90 mmHg Previous MI currently treat angina pectoris Stroke , TIA &lt; 3 month Secondary hypertension Fasting serum triglyceride &gt; 500 mg/dL Clinical congestive heart failure Uncontrolled arrhythmia Left ventricular hypertrophy : LV mass index &gt; 134g/m2 ( male ) &gt; 110g/m2 ( female ) Concomitant clinically important hematological , gastrointestinal , hepatic , renal disease Pregnant lactate woman childbearing potential Diabetes Peripheral vascular disease Unwillingness inability comply procedure describe protocol</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Statin</keyword>
</DOC>